Medical Cannabis in Pediatric Cancer: Safety Evidence for Nausea, Emerging Anti-Cancer Potential
Published cases show cannabis can safely treat chemotherapy-induced nausea in children, and preclinical evidence suggests anti-cancer effects on pediatric tumors, but research remains extremely limited.
Quick Facts
What This Study Found
Published cases demonstrate the safety and efficacy of cannabis in children for pediatric epilepsy and chemotherapy-induced nausea and vomiting. Preclinical evidence shows cannabis has anti-cancer effects on pediatric cancer cell lines. However, the endocannabinoid system develops early in life, and data about prenatal cannabis exposure show negative outcomes.
Key Numbers
Anti-cancer effects known since 1975; ECS components identified in 1990s; preclinical evidence in pediatric cancer cell lines
How They Did This
Narrative review examining published cases of cannabis use in pediatric populations, preclinical anti-cancer data on pediatric tumors, and what is known about ECS development and early-life cannabis exposure.
Why This Research Matters
Pediatric cancer treatments cause significant suffering, and options for managing side effects are limited. If cannabis can safely reduce nausea and potentially enhance cancer treatment in children, the implications are significant.
The Bigger Picture
The tension between caution about cannabis in developing brains and the reality of children suffering from cancer and its treatments demands careful research rather than blanket prohibition.
What This Study Doesn't Tell Us
Nearly all cannabis anti-cancer research has been on adults. Preclinical evidence does not guarantee clinical efficacy. ECS role in development raises legitimate safety concerns.
Questions This Raises
- ?At what age can cannabis-based treatments be considered safe for pediatric patients?
- ?Would low-THC, high-CBD formulations provide anti-cancer benefits without developmental concerns?
Trust & Context
- Key Stat:
- Anti-cancer effects of cannabis known since 1975
- Evidence Grade:
- Narrative review of case reports and preclinical data. No randomized controlled trials of cannabis as anti-cancer treatment in children.
- Study Age:
- Published in 2022
- Original Title:
- Medical Cannabis in Pediatric Oncology: Friend or Foe?
- Published In:
- Pharmaceuticals (Basel, Switzerland), 15(3) (2022)
- Authors:
- Malach, Megan, Kovalchuk, Igor(7), Kovalchuk, Olga(5)
- Database ID:
- RTHC-04032
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is cannabis safe for children with cancer?
Published cases show cannabis can safely treat chemotherapy-induced nausea and vomiting in children, and it has established safety for pediatric epilepsy. However, anti-cancer use in children has not been tested in clinical trials.
Can cannabis fight pediatric cancer?
Preclinical (lab) evidence shows cannabis has anti-cancer effects on pediatric cancer cell lines, but this has not been translated to clinical trials. The review called for further investigation.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04032APA
Malach, Megan; Kovalchuk, Igor; Kovalchuk, Olga. (2022). Medical Cannabis in Pediatric Oncology: Friend or Foe?. Pharmaceuticals (Basel, Switzerland), 15(3). https://doi.org/10.3390/ph15030359
MLA
Malach, Megan, et al. "Medical Cannabis in Pediatric Oncology: Friend or Foe?." Pharmaceuticals (Basel, 2022. https://doi.org/10.3390/ph15030359
RethinkTHC
RethinkTHC Research Database. "Medical Cannabis in Pediatric Oncology: Friend or Foe?" RTHC-04032. Retrieved from https://rethinkthc.com/research/malach-2022-medical-cannabis-in-pediatric
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.